AZD 6610

Drug Profile

AZD 6610

Alternative Names: AZD6610

Latest Information Update: 31 Jul 2007

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antihyperlipidaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Lipid metabolism disorders

Most Recent Events

  • 31 Jul 2007 Discontinued - Phase-II for Diabetes mellitus in Europe (unspecified route)
  • 31 Jul 2007 Discontinued - Phase-II for Lipid metabolism disorders in Europe (unspecified route)
  • 01 Feb 2007 Phase-II clinical trials in Diabetes mellitus in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top